Triamcinolone Acetonide as Adjunctive Treatment to Verteporfin in Neovascular Age-Related Macular Degeneration. A Prospective Randomized Trial

Ophthalmology

Volumn 114, Issue 12, 2007, Pages 2183-2189

  Chaudhary, Varun ^a   Mao, Alex ^a   Hooper, Philip L ^a   Sheidow, Tom G ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE;

ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; PHOTODYNAMIC THERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; CATARACT; CHEMOTHERAPY, ADJUVANT; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; PROSPECTIVE STUDIES; RETINA; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 36549082904     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.02.013     Document Type: Article

References (17)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
2. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
3. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123 (2005) 448-457
4. Ishibashi T., Miki K., Sorgente N., et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 103 (1985) 708-711
5. Chandler D.B., Rozakis G., de Juan Jr. E., and Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99; (1985) 686-690
6. Edelman J.L., Lutz D., and Castro M.R. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80 (2005) 249-258
7. Penfold P.L., Wong J.G., Gyory J., and Billson F.A. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 29 (2001) 188-192
8. Hageman G.S., Anderson D.H., Johnson L.V., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102 (2005) 7227-7232
9. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
10. Chan W.M., Lai T.Y., Wong A.L., et al. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 90 (2006) 337-341
11. Augustin A.J., and Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 14-22
12. Rechtman E., Danis R.P., Pratt L.M., and Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88 (2004) 344-347
13. Schmidt-Erfurth U., Schlotzer-Schrehard U., Cursiefen C., et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44 (2003) 4473-4480
14. Roth D.B., Chieh J., Spirn M.J., et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121 (2003) 1279-1282
15. Jonas J.B., Kreissig I., Hugger P., et al. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 87 (2003) 462-468
16. Jonas J.B., Degenring R.F., Kreissig I., et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye 19 (2005) 163-170
17. Jonas J.B., Degenring R.F., Kreissig I., et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112 (2005) 593-598